摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Boc-L-2-氨基己二酸 | 77302-72-8

中文名称
Boc-L-2-氨基己二酸
中文别名
BOC-L-2-氨基己二酸
英文名称
Nα-(tert-butoxycarbonyl)-L-α-aminoadipic acid
英文别名
Nα-tert-butyloxycarbonyl-L-homoglutamic acid;(S)-2-(tert-butoxycarbonylamino)hexanedioic acid;2-L-N-Boc aminoadipic acid;Boc-Aad;L-N-tert-butoxycarbonylhomoglutamic acid;(S)-2-((tert-Butoxycarbonyl)amino)hexanedioic acid;(2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]hexanedioic acid
Boc-L-2-氨基己二酸化学式
CAS
77302-72-8
化学式
C11H19NO6
mdl
——
分子量
261.275
InChiKey
QDTDLMJRZPSKDM-ZETCQYMHSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    121-122℃
  • 沸点:
    462.1±35.0 °C(Predicted)
  • 密度:
    1.231±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    18
  • 可旋转键数:
    8
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.73
  • 拓扑面积:
    113
  • 氢给体数:
    3
  • 氢受体数:
    6

安全信息

  • 危险等级:
    IRRITANT
  • WGK Germany:
    3
  • 海关编码:
    2924199090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H315,H319,H335
  • 储存条件:
    存放在室温且干燥密封的环境中。

SDS

SDS:ad75f24623e7985b434507bfca556864
查看

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : Boc-Aad-OH
CAS-No. : 77302-72-8


Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
Caution - substance not yet tested completely.
Other hazards - none

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Synonyms : Boc-L-homoglutamic acid
N-Boc-L-2-aminoadipic acid
Formula : C11H19NO6
Molecular Weight : 261,27 g/mol

Section 4. FIRST AID MEASURES
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
Indication of any immediate medical attention and special treatment needed
no data available

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: powder
Colour: white
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation
May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Additional Information
RTECS: Not available

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    Boc-L-2-氨基己二酸 在 sodium tetrahydroborate 、 三氟化硼乙醚 作用下, 以 四氢呋喃 为溶剂, 反应 2.0h, 以53%的产率得到BOC-L-6-羟基正亮氨酸
    参考文献:
    名称:
    Process for producing hydroxyamino acid derivative
    摘要:
    提供了一种高效制备羟基氨基酸衍生物的方法,特别是制备其光学活性形式。具体地,提供了一种制备由公式(I)表示的羟基氨基酸衍生物或其盐的方法:1,其特征在于,在溶剂中对由公式(II)表示的氨基酸衍生物进行侧链末端羧基的选择性还原反应,然后,可选择进行氨基保护基的消除反应或氨基或羧基的盐形成反应。
    公开号:
    US20040249205A1
  • 作为产物:
    描述:
    1-O-benzyl 4-O-(2-sulfanylidenepyridin-1-yl) (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]butanedioate 在 sodium hydroxide 作用下, 反应 1.33h, 生成 Boc-L-2-氨基己二酸
    参考文献:
    名称:
    使用自由基化学方法合成新型α-氨基酸及其衍生物:-和-α-氨基己二酸(-α)的合成
    摘要:
    由适当保护的-羟基-2-硫代吡啶酮的氨基酸衍生物经光解(W光)产生的自由基可有效地添加到活化的烯烃中,以提供令人满意的加合物收率。硫代吡啶基残基被氧化成亚砜并进行热消除,可获得极好的产率的相应的α,β-不饱和衍生物。适当保护的天冬氨酸和谷氨酸的侧链脱羧提供了L-α-和D-α-氨基己二酸,-α-氨基庚二酸和-α-氨基-δ-脱氢庚二酸的方便的合成。
    DOI:
    10.1016/s0040-4020(01)90305-9
点击查看最新优质反应信息

文献信息

  • Substrate specificity of isopenicillin N synthase
    作者:George W. Huffman、Paul D. Gesellchen、Jan R. Turner、Robert B. Rothenberger、Harold E. Osborne、F. Dean Miller、Jerry L. Chapman、Stephen W. Queener
    DOI:10.1021/jm00088a028
    日期:1992.5
    Highly purified isopenicillin N synthase (IPNS) from two sources (naturally occurring in Penicillium chrysogenum and that expressed in Escherichia coli via a cloned gene derived from Cephalosporium acremonium) have been isolated and utilized in vitro to test synthetic modifications of the natural substrate, (L-alpha-amino-delta-adipyl)-L-cysteinyl-D-valine (ACV). A very sensitive procedure utilizing
    两种来源的高纯度异青霉素N合酶(IPNS)(天然存在于产黄青霉菌中,并通过顶头孢霉的克隆基因在大肠杆菌中表达)已被分离并在体外用于测试天然底物的合成修饰(L -α-氨基-δ-己二酰基)-L-半胱氨酸-D-缬氨酸(ACV)。利用一种非常敏感的程序,利用β-内酰胺诱导β-内酰胺酶的合成,来确定ACV类似物是否可以用作IPNS的底物。检查了多种氨基和羧基末端三肽取代,发现它们引起了正的β-内酰胺酶诱导曲线。但是,没有发现这些修饰能够像ACV一样有效地用作底物。由IPNS和三肽类似物反应形成的一种β-内酰胺产物是独立合成的,并具有抗菌活性。在ACV第二个位置修饰L-半胱氨酸残基导致三肽不能用作底物。ACV第三位的D-缬氨酸残基转化为芳香族氨基酸或高负电性残基(如三氟缬氨酸)会导致底物活性消除和酶抑制剂的产生。
  • PROCESS FOR PRODUCTION OF 4-(SUBSTITUTED PHENYL)HEXAHYDROPYRIDOÝ2,1-C¨Ý1,4¨OXAZIN-6-ONE
    申请人:Eisai R&D Management Co., Ltd.
    公开号:EP2226325A1
    公开(公告)日:2010-09-08
    4-(Substituted phenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one represented by formula (I) or a salt thereof is useful as an intermediate for the production of a bicyclic cinnamide compound which is an Aβ production inhibitor. 4-(Substituted phenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one or the salt thereof can be produced in an industrially advantageous manner by subjecting a compound represented by formula (II) or a salt thereof to an intramolecular condensation reaction.
    公式(I)表示的4-(取代苯基)六氢吡啶并[2,1-c][1,4]噁唑啉-6-酮或其盐可用作生产双环丁酰胺化合物的中间体,该化合物是Aβ产生抑制剂。通过将公式(II)表示的化合物或其盐经历分子内缩合反应,可以以工业上有利的方式生产4-(取代苯基)六氢吡啶并[2,1-c][1,4]噁唑啉-6-酮或其盐。
  • The Interaction of Isopenicillin N Synthase with Homologated Substrate Analogues δ-(<scp>L</scp>-α-Aminoadipoyl)-<scp>L</scp>-homocysteinyl-<scp>D</scp>-Xaa Characterised by Protein Crystallography
    作者:Adam Daruzzaman、Ian J. Clifton、Robert M. Adlington、Jack E. Baldwin、Peter J. Rutledge
    DOI:10.1002/cbic.201200728
    日期:2013.3.18
    Loose fit: IPNS catalyses the central step in penicillin biosynthesis. Substrate analogues containing L‐homocysteine in place of the natural substrate's L‐cysteine residue are not converted into bicyclic products. Crystal structures for IPNS complexes with two such analogues reveal that the additional CH2 unit affords considerable conformational freedom when these analogues bind to IPNS.
    宽松:IPNS催化青霉素生物合成的关键步骤。包含L-高半胱氨酸代替天然底物L-半胱氨酸残基的底物类似物不会转化为双环产物。具有两个这样的类似物的IPNS配合物的晶体结构表明,当这些类似物与IPNS结合时,额外的CH 2单元可提供相当的构象自由度。
  • An Artificial β-Sheet That Dimerizes through Parallel β-Sheet Interactions
    作者:Sergiy Levin、James S. Nowick
    DOI:10.1021/ja073391r
    日期:2007.10.1
    chemical model of a β-sheet (artificial β-sheet) that dimerizes by parallel β-sheet formation in chloroform solution. The artificial β-sheet consists of two N-terminally linked peptide strands that are linked with succinic or fumaric acid and blocked along one edge with a hydrogen-bonding template composed of 5-aminoanisic acid hydrazide. The template is connected to one of the peptide strands by a turn unit
    本文介绍了 β-折叠(人工 β-折叠)的简单化学模型,该模型通过在氯仿溶液中平行 β-折叠形成而二聚化。人工 β-折叠由两条 N 端连接的肽链组成,这些肽链与琥珀酸或富马酸连接,并沿一个边缘被一个由 5-氨基茴香酸酰肼组成的氢键模板封闭。模板通过由 (S)-2-氨基己二酸 (Aaa) 组成的转向单元连接到肽链之一。1H NMR 光谱研究表明,这些人工β-折叠在CDCl3 溶液中折叠形成明确定义的β-折叠结构,通过平行β-折叠相互作用二聚化。最值得注意的是,所有这些化合物都显示出与折叠和二聚化相关的丰富的 NOE 网络。这些化合物还表现出与折叠二聚体 β-折叠结构的形成一致的化学位移和偶联常数。氨基己二酸单元显示的 NOE 模式和耦合常数与明确定义的转...
  • Crystallographic studies on the reaction of isopenicillin N synthase with an unsaturated substrate analogue
    作者:Jonathan M. Elkins、Peter J. Rutledge、Nicolai I. Burzlaff、Ian J. Clifton、Robert M. Adlington、Peter L. Roach、Jack E. Baldwin
    DOI:10.1039/b212270g
    日期:2003.4.23
    Isopenicillin N synthase (IPNS) catalyses conversion of the linear tripeptide delta-(L-alpha-aminoadipoyl)-L-cysteinyl-D-valine (ACV) to isopenicillin N (IPN), the central step in biosynthesis of the beta-lactam antibiotics. The unsaturated substrate analogue delta-(L-alpha-aminoadipoyl)-L-cysteinyl-D-vinylglycine (ACvG) has previously been incubated with IPNS and single product was isolated, a 2-alpha-hydroxymethyl
    异青霉素N合酶(IPNS)催化将线性三肽δ-(L-α-氨基己二酰基)-L-半胱氨酰-D-缬氨酸(ACV)转化为异青霉素N(IPN),这是生物合成β-内酰胺抗生素的关键步骤。先前已将不饱和底物类似物δ-(L-α-氨基己二酰基)-L-半胱氨酰-D-乙烯基甘氨酸(ACvG)与IPNS一起温育,并分离出单一产物,形成了2-α-羟甲基异青霉素N(HMPen),通过单加氧酶反应模式。ACvG现在已经用IPNS结晶,厌氧IPNS:Fe(II):ACvG络合物的结构确定为1.15 A分辨率。此外,通过将厌氧生长的晶体暴露于高压氧气中,以1.60A的分辨率获得了对应于双环产物HMPen的结构。根据这些以及其他IPNS结构,以及相关双加氧酶的最新发展,对由ACvG形成HMPen的[2 + 2]环加成机理进行了修订,并提出了逐步的自由基机理。修订后的机制与观察到的转化立体定向保持一致,但更适合于活性位铁原子周围配位几何的明显约束。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物